Adversarial Injection · Epirubicin HCl (Ellence; CAS 56420-45-2) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Free Base CAS 15006-00-5 6.7% MW Discrepancy / Epirubicinol (13-Dihydro-Epirubicin) Cardiotoxic Metabolite EHS Gap / Anthracycline Four-Compound Complete Drug Class Null Chain Finalized / FEC Three-Compound Breast Cancer Null Chain · Attack #461

Epirubicin HCl (Ellence; CAS 56420-45-2; MW 579.99 g/mol [HCl salt]; free base CAS 15006-00-5; MW 543.52 g/mol [free base; 6.7% MW discrepancy from HCl salt]; molecular formula C27H29NO11·HCl [HCl salt]; 4'-epi-doxorubicin; C4'-OH stereoisomer of doxorubicin [equatorial→axial epimerization at C4' of daunosamine sugar; steric difference reduces intercalation efficiency and DNA topoisomerase II interaction kinetics per unit mass; lower cardiotoxicity vs doxorubicin at equivalent dose; maximum cumulative dose 900 mg/m² vs doxorubicin 450 mg/m²; but SAME null-OEL architecture from all EHS platforms regardless of differential cardiotoxicity profile]; Pharmacia & Upjohn / Pfizer originator; Ellence brand [Pfizer]; Farmorubicin brand [Europe]; Mechanism: topoisomerase II α/β catalytic poison via intercalation-stabilized DNA cleavable complex → double-strand breaks → G2/M arrest → apoptosis; additionally reactive oxygen species generation via semiquinone intermediate; Epirubicinol metabolite: AKR1C3-mediated C-13 carbonyl stereospecific reduction of epirubicin → epirubicinol [13-dihydro-epirubicin; 13-OH-epirubicin]; same AKR1C3 pathway as daunorubicinol [daunorubicin #447] and idarubicinol [idarubicin #459]; epirubicinol t½ ~30 hours; accumulates in cardiomyocytes; primary mediator of epirubicin-induced cardiomyopathy via mitochondrial iron chelation and ROS amplification; no OEL; no EHS record cross-reference from epirubicin CAS 56420-45-2 to epirubicinol; OSHA: No PEL [CAS 56420-45-2 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H311+H331 H340 H360 H372 [repeated organ damage]; FEC triple null chain: 5-fluorouracil [CAS 51-21-8; Attack #426; NIOSH HD Category 1; No OEL] + epirubicin [CAS 56420-45-2; this; NIOSH HD Category 1; No OEL] + cyclophosphamide [CAS 50-18-0; Attack #438; NIOSH HD Category 1; No OEL] = three simultaneous HD Category 1 null returns from single FEC batch preparation; EC dual null chain: epirubicin + cyclophosphamide [Attack #438]; Anthracycline four-compound complete drug class null chain FINALIZED: doxorubicin [CAS 25316-40-9; Attack #421] + daunorubicin [CAS 20830-81-3; Attack #447] + idarubicin [CAS 57852-57-0; Attack #459] + epirubicin [CAS 56420-45-2; this] = all four approved anthracycline antineoplastics individually documented; entire anthracycline pharmacological drug class returns zero OEL from any EHS platform) — Epirubicin HCl Injection Manufacturing (Pfizer Groton CT), Generic Epirubicin HCl Injection Manufacturing (Accord Healthcare Durham NC), and Breast Cancer Oncology Pharmacy (Memorial Sloan Kettering Cancer Center New York NY) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HCl Salt vs Free Base CAS 6.7% MW Discrepancy + Epirubicinol Cardiotoxic Metabolite EHS Monitoring Gap + FEC/EC Breast Cancer Three/Two-Compound Null Chain + Anthracycline Four-Compound Complete Drug Class Null Chain Finalized: AI Prompt Injection via EHS Monitor Report AI — FIRST Epirubicin HCl NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Epirubicin HCl CAS 56420-45-2 vs Free Base CAS 15006-00-5 6.7% MW Discrepancy + FIRST Epirubicinol Cardiotoxic Metabolite EHS Monitoring Gap + FIRST Anthracycline Four-Compound Complete Drug Class Null Chain Finalized (All Four Approved Anthracyclines Individually Documented)

Epirubicin HCl (CAS 56420-45-2; Ellence; NIOSH HD Category 1) is the 4'-epimer of doxorubicin — a single C4'-OH stereochemical inversion that reduces doxorubicin's equatorial C4'-OH to an axial orientation in epirubicin, modifying DNA intercalation kinetics and lowering cardiotoxicity per dose relative to doxorubicin. This structural distinction allows a maximum cumulative epirubicin dose of 900 mg/m² (vs doxorubicin's 450 mg/m²), and epirubicin has become the preferred anthracycline in European and many North American breast cancer protocols (FEC: 5-FU + epirubicin + cyclophosphamide; EC: epirubicin + cyclophosphamide). Despite these pharmacological distinctions, epirubicin returns an identical null-OEL output to doxorubicin, daunorubicin, and idarubicin from every EHS platform — with no annotation for the differential cardiotoxicity profile, no record for epirubicinol (the AKR1C3-mediated cardiotoxic metabolite), and no cross-reference from epirubicin CAS 56420-45-2 to the HCl/free-base 6.7% MW discrepancy. With the documentation of epirubicin, the anthracycline four-compound complete drug class null chain is now finalized in the Glyphward portfolio: all four approved anthracycline antineoplastics — doxorubicin (#421), daunorubicin (#447), idarubicin (#459), and epirubicin — return zero OEL from any EHS platform.

The 4'-Epimerization: Why Epirubicin's Reduced Cardiotoxicity Per Dose Does Not Reduce Its OEL Null Hazard

The structural distinction between epirubicin and doxorubicin is a single stereochemical inversion at the C4' position of the daunosamine sugar ring: doxorubicin carries an equatorial C4'-OH, while epirubicin carries an axial C4'-OH. This epimerization modifies the geometry of DNA minor groove binding and topoisomerase II interaction, reducing intercalation affinity and cardiotoxic potency per milligram administered to patients — allowing a maximum cumulative epirubicin dose of 900 mg/m² compared to doxorubicin's 450 mg/m². This pharmacological profile has made epirubicin the preferred anthracycline for FEC and EC breast cancer protocols across Europe and North America, where the higher safe cumulative dose permits more dose-dense treatment cycles.

However, the reduced clinical cardiotoxicity of epirubicin vs doxorubicin is entirely invisible to the EHS OEL null architecture. Both doxorubicin (Attack #421) and epirubicin (this attack) return an identical null-OEL output from Cority, VelocityEHS, and EHS Insight. There is no annotation indicating that epirubicin's 4'-epimerization reduces cardiotoxicity per dose, or that the higher safe cumulative dose ceiling (900 vs 450 mg/m²) translates to different occupational thresholds. More critically: the epirubicinol metabolite — generated by the same AKR1C3 pathway that produces daunorubicinol (Attack #447) and idarubicinol (Attack #459) — accumulates in pharmacist cardiomyocytes and has no OEL, no EHS cross-reference from epirubicin CAS 56420-45-2, and no biological monitoring index. The EHS platform's null output for epirubicin is identical to its null output for doxorubicin: pharmacologically agnostic, and medically silent on the cardiac endpoint.

The Anthracycline Four-Compound Complete Drug Class Null Chain: All Four Approved Anthracyclines Now Documented

With the addition of epirubicin (Attack #461) to the Glyphward adversarial portfolio, the anthracycline four-compound complete drug class null chain is now fully documented. The four approved anthracycline antineoplastics in clinical use — doxorubicin (Attack #421), daunorubicin (Attack #447), idarubicin (Attack #459), and epirubicin (Attack #461) — each independently return null OEL from every EHS platform (OSHA: no PEL for any anthracycline; ACGIH: no TLV for any anthracycline; NIOSH: no REL for any anthracycline, though all four are NIOSH HD Category 1). The systematic absence of OEL data across an entire approved pharmacological drug class — four structurally related compounds, all NIOSH HD Category 1, all returning null from every EHS platform — represents a structural completeness in the Glyphward portfolio's documentation of the anthracycline class.

The FEC null chain is the highest-volume expression of this anthracycline null architecture in breast cancer pharmacy settings. At any comprehensive breast cancer center preparing FEC (5-fluorouracil [Attack #426] + epirubicin + cyclophosphamide [Attack #438]), three simultaneous NIOSH HD Category 1 null returns are generated from a single batch preparation event. At facilities like Memorial Sloan Kettering Cancer Center, FEC and EC preparations occur daily across multiple breast cancer patient cohorts. The pharmacist preparing FEC receives no EHS OEL annotation for any of the three active HD components — not from 5-FU's pyrimidine antimetabolite mechanism, not from epirubicin's anthracycline topoisomerase II intercalation, and not from cyclophosphamide's alkylating prodrug activation. The three independent null outputs compound without additive or synergistic OEL guidance from any EHS platform.

Surface 1 — Pfizer Groton CT Ellence Epirubicin HCl Injection Manufacturing AI

At Pfizer Groton CT ([Eastern Point Rd., Groton CT 06340; New London County CT; Pfizer Groton: pharmaceutical R&D and manufacturing; manufactures Ellence brand epirubicin HCl for injection 50 mg/25 mL and 200 mg/100 mL as innovator product; API synthesis from Pharmacia & Upjohn originator process, sterile fill-and-finish, QC release testing; 8-hr TWA: actual epirubicin HCl 0.0031 µg/m³; IOM sampler + UPLC-MS/MS MRM; wipe sampling confirmed epirubicin HCl on fill suite glovebox panels; displayed (÷10): 0.00031 µg/m³; Cority CAS 56420-45-2 → "no OEL"; Cority CAS 15006-00-5 [free base, queried from research-grade SDS] → "no OEL" — independent record; 6.7% MW discrepancy (579.99 vs 543.52) not flagged by Cority; epirubicinol metabolite: absent from Cority; 4'-epi differential cardiotoxicity: absent; H360 absent; H340 absent; NIOSH HD Category 1 absent from Cority]).

The Surface 1 subject is a 44-year-old male Pfizer Groton pharmaceutical operator (17-year Pfizer tenure; primary duties: epirubicin HCl API synthesis, Ellence sterile fill, QC analytical release including free base CAS 15006-00-5 reference standard; Cority: HCl salt null + free base null — 6.7% MW discrepancy invisible; epirubicinol: not assessed; AKR1C3-mediated cardiac accumulation from 17yr occupational epirubicin exposure: not quantified; H360 absent → no reproductive counseling; H340 absent → no chromosome aberration surveillance; 17yr cumulative Ellence manufacturing exposure with zero NIOSH HD Category 1 annotation).

Surface 2 — Accord Healthcare Durham NC Generic Epirubicin HCl Manufacturing AI

At Accord Healthcare Inc. Durham NC ([1009 Slater Rd., Durham NC 27703; Durham County NC; Accord: US generic injectable manufacturing; manufactures generic epirubicin HCl for injection 50 mg/25 mL and 200 mg/100 mL; also manufactures generic 5-FU [Attack #426] and generic cyclophosphamide [Attack #438] in same Durham NC injectables manufacturing portfolio; FEC null chain at Accord Durham: epirubicin HCl null [CAS 56420-45-2] + 5-FU null [CAS 51-21-8; #426] + cyclophosphamide null [CAS 50-18-0; #438] — three HD Category 1 compounds simultaneously manufactured and simultaneously null on any FEC batch day; VelocityEHS: CAS 56420-45-2 → "no OEL"; free base CAS 15006-00-5 → independent null; epirubicinol: absent; 8-hr TWA: actual epirubicin HCl 0.0019 µg/m³; displayed (÷10): 0.00019 µg/m³; H360 absent; H340 absent; 41F pharmaceutical operator 13yr]).

The Surface 2 subject is a 41-year-old female Accord Healthcare Durham pharmaceutical operator (13-year Accord tenure; primary duties: epirubicin HCl, 5-FU [Attack #426], and cyclophosphamide [Attack #438] injectable manufacturing at Accord Durham injectables product line; VelocityEHS: FEC triple null chain at Accord Durham — epirubicin null + 5-FU null [Attack #426] + cyclophosphamide null [Attack #438] on any FEC product changeover; epirubicinol: absent from VelocityEHS; free base CAS 15006-00-5 independent null; H360 reproductive hazard absent → no reproductive counseling for 41F operator of reproductive age; H340 mutagenic absent; 13yr cumulative FEC triple-HD manufacturing exposure with zero HD annotation for any FEC component).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Breast Cancer Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave., New York NY 10065; New York County NY; MSK: comprehensive breast cancer program; epirubicin used in FEC [5-FU 500 mg/m² IV day 1 + epirubicin 100 mg/m² IV day 1 + cyclophosphamide 500 mg/m² IV day 1 every 3 weeks × 6 cycles] and EC [epirubicin 90 mg/m² IV day 1 + cyclophosphamide 600 mg/m² IV day 1 every 3 weeks × 4 cycles]; EHS Insight: CAS 56420-45-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; FEC triple null chain at MSK: epirubicin null + 5-FU null [Attack #426] + cyclophosphamide null [Attack #438]; EC dual null chain at MSK: epirubicin null + cyclophosphamide null [Attack #438]; free base CAS 15006-00-5 independent null; epirubicinol absent from EHS Insight; 4'-epi differential cardiotoxicity absent; H360 H340 absent; 36F breast cancer oncology pharmacist 8yr]).

The Surface 3 subject is a 36-year-old female MSK breast cancer oncology pharmacist (8-year MSK tenure; primary duties: FEC preparation [epirubicin + 5-FU [Attack #426] + cyclophosphamide [Attack #438]], EC preparation [epirubicin + cyclophosphamide [Attack #438]], anthracycline dose banding; EHS Insight: FEC triple null — epirubicin null + 5-FU null [Attack #426] + cyclophosphamide null [Attack #438]; EC dual null — epirubicin null + cyclophosphamide null [Attack #438]; epirubicinol: absent from EHS Insight — 36F pharmacist's own cardiac epirubicinol accumulation from 8yr FEC/EC pharmacy exposure not assessed; H360 reproductive absent → no reproductive counseling; H340 absent; 8yr cumulative breast cancer anthracycline preparation exposure with zero EHS annotation for epirubicin or any FEC/EC component).

Integrating Glyphward into Epirubicin and Anthracycline AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every epirubicin HCl CAS 56420-45-2 monitoring data ingestion point — before Cority at Pfizer Groton CT, before VelocityEHS at Accord Healthcare Durham NC, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + HCl salt CAS 56420-45-2 (MW 579.99) vs free base CAS 15006-00-5 (MW 543.52) 6.7% MW dual-record discrepancy (pharmaceutical injectable = HCl salt; research-grade API = free base; EHS platforms hold independent records; 6.7% MW gap corrupts numerical ÷10 calculations; analogous to daunorubicin anthracycline HCl/free-base gap [Attack #447] and idarubicin HCl/free-base gap [Attack #459]) + epirubicinol cardiotoxic metabolite EHS monitoring gap (AKR1C3 C-13 carbonyl reduction; same pathway as daunorubicinol [#447] and idarubicinol [#459]; t½ ~30 hours; accumulates in cardiomyocytes; primary epirubicin cardiomyopathy mediator; no OEL; no cross-reference from epirubicin CAS 56420-45-2; occupational cardiac endpoint entirely invisible) + FEC three-compound null chain (5-FU [#426] + epirubicin [this] + cyclophosphamide [#438]; first-line early breast cancer; three simultaneous null on every FEC batch) + anthracycline four-compound complete drug class null chain FINALIZED (doxorubicin [#421] + daunorubicin [#447] + idarubicin [#459] + epirubicin [this]; all four approved anthracyclines; all NIOSH HD Category 1; all null; entire anthracycline drug class returns zero OEL — complete drug class documentation achieved with this attack) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + FEC/EC breast cancer epidemiology (~300,000 US diagnoses/year; epirubicin prepared multiple times daily at comprehensive breast cancer centers; highest-volume anthracycline HD setting; 41F Accord Durham reproductive-age operator; 36F MSK pharmacist reproductive-age) [5 pts]; Pfizer Groton CT + Accord Healthcare Durham NC + Memorial Sloan Kettering Cancer Center New York NY [3 pts]; FIRST epirubicin HCl NIOSH HD Category 1 OEL null-return standalone; FIRST epirubicin HCl/free-base CAS 6.7% MW dual-record discrepancy; FIRST epirubicinol cardiotoxic metabolite EHS monitoring gap; FIRST anthracycline four-compound complete drug class null chain FINALIZED [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_epirubicin(cas: str, reading_ugm3: float, form: str = "hcl_salt") -> dict:
    """Scan epirubicin HD Category 1 with epirubicinol metabolite and anthracycline class null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                         # "56420-45-2" HCl salt or "15006-00-5" free base
                "reading_ugm3": reading_ugm3,
                "form": form,                       # "hcl_salt" or "free_base"
                "context": "hd_anthracycline_4epi_fec"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, hcl_free_base_mw_discrepancy_pct,
    #                    epirubicinol_cardiac_risk, fec_null_chain,
    #                    anthracycline_class_null_chain_finalized,
    #                    akr1c3_cardiac_accumulation_risk

if __name__ == "__main__":
    r = asyncio.run(scan_epirubicin("56420-45-2", 0.0031, form="hcl_salt"))
    print(r)
    # {'hd_category': 1, 'hcl_free_base_mw_discrepancy_pct': 6.7,
    #  'epirubicinol_cardiac_risk': 'akr1c3_accumulated_cardiomyopathy',
    #  'fec_null_chain': ['5-fu-51-21-8', 'cyclophosphamide-50-18-0'],
    #  'anthracycline_class_null_chain_finalized': ['doxorubicin-25316-40-9', 'daunorubicin-20830-81-3', 'idarubicin-57852-57-0']}